Trials / Completed
CompletedNCT00290940
Evaluation of Glucose Lowering Effect, Safety and Tolerability of CS-917
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of CS-917 as Monotherapy for Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study will compare glucose lowering with CS-917 compared to placebo after 3 months of treatment
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CS-917 | |
| DRUG | metformin hydrochloride | |
| DRUG | pioglitazone |
Timeline
- Start date
- 2006-01-01
- Completion
- 2007-04-01
- First posted
- 2006-02-13
- Last updated
- 2007-09-11
Locations
66 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00290940. Inclusion in this directory is not an endorsement.